These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1413 related items for PubMed ID: 12576815

  • 1. T2a transitional cell carcinoma of the bladder: long-term experience with intravesical immunoprophylaxis with bacillus Calmette-Guerin.
    Volkmer BG, Gschwend JE, Maier SH, Seidl-Schlick EM, Bach D, Romics I.
    J Urol; 2003 Mar; 169(3):931-4; discussion 934-5. PubMed ID: 12576815
    [Abstract] [Full Text] [Related]

  • 2. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
    Peyromaure M, Guerin F, Amsellem-Ouazana D, Saighi D, Debre B, Zerbib M.
    J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
    [Abstract] [Full Text] [Related]

  • 3. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin.
    Brake M, Loertzer H, Horsch R, Keller H.
    J Urol; 2000 Jun; 163(6):1697-701. PubMed ID: 10799163
    [Abstract] [Full Text] [Related]

  • 4. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
    Wo JY, Shipley WU, Dahl DM, Coen JJ, Heney NM, Kaufman DS, Zietman AL.
    BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
    [Abstract] [Full Text] [Related]

  • 5. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED.
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [Abstract] [Full Text] [Related]

  • 6. Recurrence and progression of T1G3 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guérin.
    Günlüsoy B, Değirmenci T, Arslan M, Nergiz N, Minareci S, Ayder AR.
    Urol Int; 2005 Apr; 75(2):107-13. PubMed ID: 16123562
    [Abstract] [Full Text] [Related]

  • 7. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
    Librenjak D, Situm M, Eterovic D, Dogas Z, Gotovac J.
    Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
    [Abstract] [Full Text] [Related]

  • 8. High grade superficial (G3t1) transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guerin (BCG).
    Pansadoro V, Emiliozzi P, depaula F, Scarpone P, Pizzo M, Federico G, Martini M, Pansadoro A, Sternberg CN.
    J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):223-7. PubMed ID: 16767936
    [Abstract] [Full Text] [Related]

  • 9. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E, Fujimoto H, Mizutani Y, Okajima E, Koga H, Hinotsu S, Shinohara N, Oya M, Miki T, Cancer Registration Committee of the Japanese Urological Association.
    Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
    [Abstract] [Full Text] [Related]

  • 10. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
    Friedrich MG, Pichlmeier U, Schwaibold H, Conrad S, Huland H.
    Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
    [Abstract] [Full Text] [Related]

  • 11. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
    Lerner SP, Tangen CM, Sucharew H, Wood D, Crawford ED.
    J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
    [Abstract] [Full Text] [Related]

  • 12. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
    Lebret T, Bohin D, Kassardjian Z, Herve JM, Molinie V, Barre P, Lugagne PM, Botto H.
    J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
    [Abstract] [Full Text] [Related]

  • 13. Reassessment of conservative management for stage T1N0M0 transitional cell carcinoma of the bladder.
    Zhang GK, Uke ET, Sharer WC, Borkon WD, Bernstein SM.
    J Urol; 1996 Jun; 155(6):1907-9. PubMed ID: 8618284
    [Abstract] [Full Text] [Related]

  • 14. [Initial conservative treatment for grade 3 Ta-1 superficial bladder cancer].
    Fujimoto K, Chihara Y, Kondo H, Hirao Y.
    Hinyokika Kiyo; 2006 Jun; 52(6):433-8. PubMed ID: 16848356
    [Abstract] [Full Text] [Related]

  • 15. Bacillus Calmette-Guerin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: long-term results.
    Pansadoro V, Emiliozzi P, Defidio L, Donadio D, Florio A, Maurelli S, Lauretti S, Sternberg CN.
    J Urol; 1995 Dec; 154(6):2054-8. PubMed ID: 7500457
    [Abstract] [Full Text] [Related]

  • 16. Immunoprophylaxis of superficial bladder cancer: a prospective and randomized comparison of oral versus intravesical Bacillus Calmette-Guerin.
    Netto Júnior NR, Levi d'Ancona CA, Claro JF, Ilari O.
    Arch Esp Urol; 1991 Oct; 44(8):1025-8. PubMed ID: 1796850
    [Abstract] [Full Text] [Related]

  • 17. Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors.
    Palou J, Laguna P, Millán-Rodríguez F, Hall RR, Salvador-Bayarri J, Vicente-Rodríguez J.
    J Urol; 2001 May; 165(5):1488-91. PubMed ID: 11342902
    [Abstract] [Full Text] [Related]

  • 18. The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study.
    Yutkin V, Pode D, Pikarsky E, Mandelboim O.
    J Urol; 2007 Dec; 178(6):2660-4. PubMed ID: 17945285
    [Abstract] [Full Text] [Related]

  • 19. Clinical outcome of high-grade non-muscle-invasive bladder cancer: a long-term single center experience.
    Iida S, Kondo T, Kobayashi H, Hashimoto Y, Goya N, Tanabe K.
    Int J Urol; 2009 Mar; 16(3):287-92. PubMed ID: 19207115
    [Abstract] [Full Text] [Related]

  • 20. Intravesical bacillus Calmette-Guérin therapy for T1 superficial bladder cancer.
    Demkow T, Alter A, Wiechno P.
    Urol Int; 2008 Mar; 80(1):74-9. PubMed ID: 18204238
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 71.